pSivida silicon for diagnostics
Australian nanotechnology company pSivida, which earlier this year revealed it has designs on the drug delivery market, has created a wholly owned spin-off diagnostics company, AION Diagnostics.
Archives for September 26, 2004
Buckyballs: study finds toxicity, and a cure
Researchers at Rice in the US have demonstrated a simple way to reduce the toxicity of water-soluble buckyballs by a factor of more than ten million.
Novartis plans oral growth hormone
Emisphere Technologies of the US has entered into a licensing deal with Swiss drug major Novartis to develop an oral formulation of recombinant growth hormone, currently administered by injection.
Qiagen acquires Molecular Staging assets
Dutch biotech firm Qiagen has announced the acquisition of key assets of Molecular Staging (MSI), which includes the Whole Genome Amplification (WGA) technology, designed to eliminate limitations created by scarce quantities of DNA samples.
Smart container for dangerous chemicals
Bonar Plastics has developed a new container for hazardous liquids that reduces the risk of spillages, is easy and safe for operators to clean, and can be monitored using wireless technologies.
Study reports changing drug R&D trends in cancer
A new report into pharmaceutical R&D worldwide identifies a changing trend in increasing R&D focus of drugs for breast cancer treatment compared with those for prostate cancer. This may account for prostate cancer becoming the second most dangerous...
Targeted HIV protein leads to new drugs
The recent surge in HIV research shows no sign of terminating as researchers reported the successful targeting of an HIV protein that has eluded existing therapies. The technique used for identifying the synthetic molecules may also lead to new drug...
Computer program builds novel drugs
Austrian company Inte:Ligand, which specializes in the development of new drugs by computer simulation has launched a new software package for modern drug design, which will provide pharma companies with a tool to speed up the entire drug development...
Anthrax images aids better drug design
Sulfa drugs, the primary therapy for treating anthrax, are losing the battle in its effectiveness in treating this bacterium, of which antibiotic-resistant strains are emerging. Now, computer-generated images which show bacterium enzyme mutations has...
New ultrasound processor
The US subsidiary of Germany's Dr Hielscher has introduced a new ultrasound device for the formation of aerosols that could have a role in sample processing and quality control.